Sonoma Pharmaceuticals, Inc.
SNOA
$3.24
-$0.03-0.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.60M | 4.02M | 3.75M | 3.56M | 3.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.60M | 4.02M | 3.75M | 3.56M | 3.58M |
| Cost of Revenue | 3.48M | 2.55M | 2.23M | 2.29M | 2.22M |
| Gross Profit | 2.12M | 1.46M | 1.53M | 1.27M | 1.36M |
| SG&A Expenses | 1.88M | 1.97M | 1.77M | 1.87M | 1.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.94M | 5.11M | 4.41M | 4.60M | 4.43M |
| Operating Income | -337.00K | -1.10M | -656.00K | -1.03M | -850.00K |
| Income Before Tax | -731.00K | -1.24M | -528.00K | -919.00K | -463.00K |
| Income Tax Expenses | -197.00K | -1.00K | 248.00K | 9.00K | 147.00K |
| Earnings from Continuing Operations | -534.00K | -1.24M | -776.00K | -928.00K | -610.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -534.00K | -1.24M | -776.00K | -928.00K | -610.00K |
| EBIT | -337.00K | -1.10M | -656.00K | -1.03M | -850.00K |
| EBITDA | -301.00K | -1.06M | -625.00K | -998.00K | -815.00K |
| EPS Basic | -0.32 | -0.76 | -0.48 | -0.63 | -0.59 |
| Normalized Basic EPS | -0.28 | -0.47 | -0.20 | -0.39 | -0.28 |
| EPS Diluted | -0.32 | -0.76 | -0.48 | -0.63 | -0.59 |
| Normalized Diluted EPS | -0.28 | -0.47 | -0.20 | -0.39 | -0.28 |
| Average Basic Shares Outstanding | 1.65M | 1.64M | 1.61M | 1.46M | 1.03M |
| Average Diluted Shares Outstanding | 1.65M | 1.64M | 1.61M | 1.46M | 1.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |